Antipsychotics as antidepressants

@article{Roberts2016AntipsychoticsAA,
  title={Antipsychotics as antidepressants},
  author={Rona Jeannie Roberts and Kavita Lohano and Rif S El-Mallakh},
  journal={Asia‐Pacific Psychiatry},
  year={2016},
  volume={8},
  pages={179 - 188}
}
Three second‐generation antipsychotic (SGA) agents have received FDA approval for adjunctive treatment, to antidepressant, of major depressive disorder: quetiapine, aripiprazole, and olanzapine. Additionally, quetiapine and lurasidone have been approved for the treatment of bipolar depression. There are data suggesting that quetiapine is effective for major depressive disorder as monotherapy. These agents are effective for depression only at subantipsychotic doses. Receptor profiles predict… Expand
Evaluating lurasidone as a treatment option for bipolar disorder
TLDR
Lurasidone has not demonstrated efficacy in relapse prevention when added to a mood stabilizer but is safe in combination with other medications. Expand
Update on schizophrenia and bipolar disorder: focus on cariprazine
TLDR
This review will provide clinicians with basic information regarding the research program of cariprazine, a new, novel antipsychotic medication with dopamine D2 and D3 partial agonist effects with unclear effectiveness in depression associated with unipolar or bipolar illness. Expand
The Place of Antipsychotics in the Therapy of Anxiety Disorders and Obsessive-Compulsive Disorders
TLDR
Contrary to SAD and PD, this review found evidence for the use of second-generation antipsychotics in GAD and OCD, and first-generation anti-anxiety drugs cannot be recommended in anxiety disorders and OCD. Expand
Advances in the psychopharmacotherapy of bipolar disorder type I
TLDR
Recent effectiveness studies continue to confirm the superiority of lithium and other mood stabilizers in the management of bipolar illness for both psychiatric and medical outcomes, reaffirming their role as foundational treatments in the Management of type I bipolar disorder. Expand
Atypical Antipsychotics in the Treatment of Acute Bipolar Depression with Mixed Features: A Systematic Review and Exploratory Meta-Analysis of Placebo-Controlled Clinical Trials
TLDR
Overall, SGAs appear to offer favorable improvements in MADRS and YMRS scores vs. placebo, and additional original studies are required to allow more reliable and clinically definitive conclusions. Expand
Different molecular targets, one purpose – treatment of depression
Abstract Although vast scientific progress has been made, the current pharmacotherapy of depression is still not fully effective. In adults, depressive disorders are among the most common diseases inExpand
A retrospective naturalistic study on the psychopharmacological treatment of schizoaffective disorder
TLDR
The role of antipsychotics as the essential psychopharmacological treatment for different symptoms of schizoaffective disorder is corroborate, however, the role of mood stabilizers, antidepressants or BZD is controversial and should be individually considered. Expand
A 12-Month Open-Label Extension Study of the Safety and Tolerability of Lisdexamfetamine Dimesylate for Major Depressive Disorder in Adults
TLDR
The overall safety and tolerability of long-term LDX augmentation of antidepressant monotherapy was consistent with the profiles of the short-term antecedent studies, with no evidence of new safety signals. Expand
Quetiapine reverses paclitaxel-induced neuropathic pain in mice: Role of alpha2- adrenergic receptors
TLDR
Results indicate that quetiapine, when administered after nerve injury can reverse the expression of neuropathic pain and conclude that α2-adrenoceptors participate in the antinociceptive effects of quetuapine. Expand
Effect of N-Desalkylquetiapine/Quetiapine Plasma Level Ratio on Anxiety and Depression in Bipolar Disoder: A Prospective Observational Study: Erratum.
TLDR
The findings confirm the efficacy of quetiapine on depressive symptoms, and the available data support that quetuapine's antidepressant activity is mediated by the active metabolite norquetiapines. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 114 REFERENCES
Treatment Strategies for Dosing the Second Generation Antipsychotics
TLDR
The second generation antipsychotics are clearly delineated in the treatment of psychosis and mania and share similar mechanisms of action to achieve these results: dopamine‐2 receptor antagonism for efficacy and serotonin‐2a receptor antagonists for EPS tolerability. Expand
Second-generation antipsychotics in major depressive disorder: update and clinical perspective
TLDR
Both SGA monotherapy and adjunctive therapy showed greater efficacy in the treatment of MDD than placebo, but augmentation is more widely utilized in treatment-resistant depression. Expand
Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder.
TLDR
A possible augmentation role for ziprasidone when used in conjunction with SSRIs in SSRI-resistant MDD is suggested, with no clinically significant QTc prolongation or severe adverse events observed in any of the study participants. Expand
Quetiapine: a review of its use in the management of bipolar depression.
TLDR
In a randomized, double-blind, placebo-controlled trial, quetiapine maintenance therapy for up to 104 weeks was more efficacious than placebo or lithium in prolonging the time to recurrence of any mood event and of depression mood events, but not of hypomanic/manic events. Expand
The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.
TLDR
Ziprasidone targets the key hypothetical neurochemical disturbance in psychosis-excessive dopamine neurotransmission at dopamine D2 receptors in the mesolimbic pathway of the brain-presumably responsible for the positive symptoms of schizophrenia. Expand
The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder.
TLDR
Although limited by its design, this study suggests atypical neuroleptic augmentation of antidepressants may be a viable option in treatment-resistant major depressive disorder. Expand
Risperidone, an atypical antipsychotic enhances the antidepressant-like effect of venlafaxine or fluoxetine: Possible involvement of alpha-2 adrenergic receptors
TLDR
The results of the present study suggest that the beneficial consequences of addition of risperidone with venlafaxine or fluoxetine in mouse forced swim test may involve alpha-2 adrenergic receptors. Expand
Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.
TLDR
Olanzapine is more effective than placebo, and combined olanzapine-fluoxetine isMore effective than olanZapine and placebo in the treatment of bipolar I depression without increased risk of developing manic symptoms. Expand
Aripiprazole Augmentation in Major Depressive Disorder: A Double-Blind, Placebo-Controlled Study in Patients with Inadequate Response to Antidepressants
TLDR
This is the third consecutive clinical trial to demonstrate that aripiprazole augmentation to antidepressants is an efficacious and well-tolerated treatment for patients with MDD who do not respond adequately to standard antidepressant monotherapy. Expand
Adjunctive Low-Dose Aripiprazole With Standard-Dose Sertraline in Treating Fresh Major Depressive Disorder: A Randomized, Double-Blind, Controlled Study
TLDR
The primitive data showed that adjunctive low-dose aripiprazole could augment the efficacy of regular-dose sertraline in fresh major depressive disorder. Expand
...
1
2
3
4
5
...